BioIVT buys Ascendance Biotechnology

| By | Biotechnologies, Stem Cells
0
199

BioIVT, a leading provider of biospecimens and related services, announced that it has acquired Ascendance Biotechnology.

Ascendance was formed in November 2015 from the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. to form a multinational cell-based assay company. As a result, BioIVT is adding Hepregen’s HepatoPac®, HepatoMune™ and HepatoStem™ liver cell and stem cell product lines to its drug safety testing and toxicology portfolios.

Hepregen’s products employ a patented cell micropatterning technology in which different cell types are plated on industry-standard microwell plates in proprietary patterns. The plates provide in vitro cellular co-cultures that have a longer life and improved function.

BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services and specializes in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids.

SOURCE: bioIVT
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.